First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.Yakun Wang, Lin Shen, Jufeng Wang et al.|Journal of Clinical Oncology|2023Cited by 32
Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter StudyJian Li, Lin Shen, Xinhua Zhang et al.|The Oncologist|2022Cited by 14